サマリー

レポートの範囲

本レポートは、重症筋無力症治療の世界市場規模を包括的に調査することを目的としています。現在および過去の市場収益は、製品タイプ、薬剤別治療法、地域に基づいて推定することができます。

レポートは以下を含みます：

- 54のデータ表と47の追加表
- 重症筋無力症（MG）治療薬の世界市場の概要と分析
- 2020年～2022年の過去の市場収益データ（売上高）、2023年の予測、2028年までの複合年間成長率（CAGR）の予測による市場動向の分析
- 製品、タイプ、治療モダリティ、地域に基づくMG治療の市場規模、収益予測、潜在成長シェア分析
- 市場に影響を与える主な要因（促進要因、阻害要因、機会、課題）に関する詳細情報（事実と数値）
- 一般的なミクロおよびマクロ環境要因を考慮した、ポーターのファイブフォースおよびPESTLE分析による市場成長機会の分析
- 消費者態度、リスクと機会、製薬・バイオ企業のESG活動を考慮した重症筋無力症市場におけるESGの重要性の検討
- 市場牽引要因、業界動向、新規開発に関する考察
- 関連特許の分析
- MG分野のリーダーの特定
- 主要市場プレイヤーのプロファイル（AbbVie、Bausch Health、Gilead Sciences、Merck & Co.Inc.、Servier社、Teva社

ページTOPに戻る

目次

Table of Contents
Chapter 1 Introduction
Study Goals and Objectives
Reasons for Doing This Study
Scope of Report
Methodology
Information Sources
Primary Research
Secondary Research
Geographic Breakdown
Segmentation Breakdown
Chapter 2 Summary and Highlights
Market Outlook
Report Highlights
Chapter 3 Market Overview
Myasthenia Gravis
Ocular Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Global Regulatory Structure for Myasthenia Gravis
Drug Approvals and Regulation
Clinical Trials
Patient Access and Health Insurance
Pharmaceutical Pricing and Reimbursement
Clinical Practice Guidelines
Rare Disease Designation
Patient Advocacy and Support
Pricing and Reimbursement for the Treatment of Myasthenia Gravis
North America
Europe
Asia-Pacific
Therapies/Drugs Used to Treat Myasthenia Gravis
Medications
Surgery
Intravenous (IV) Therapy
Medications
Chapter 4 Market Dynamics
Market Drivers
Growing Elderly Population
Increasing Incidence and Prevalence
Advancements in Myasthenia Gravis Diagnostics
Research and Development
Regulatory Environment
Personalized Medicine
Market Opportunities
Unmet Medical Needs
Advancements in Research and Development
Biologics and Immunotherapies
Global Expansion
Increased Awareness
Tailored Treatment Approaches
Healthcare Reimbursement
Patient-Centric Care
Competitive Landscape
Chronic Nature of Myasthenia Gravis
Research Collaboration
Market Restraints
Limited Patient Population
Diagnostic Challenges
Lack of Disease-Modifying Therapies
Reimbursement Issues
Risks of Emerging Therapies
Other Restraints
Chapter 5 Market Breakdown by Region
Market Overview
North America
Europe
Asia-Pacific
Chapter 6 Market Breakdown by Type
Market Overview
Generalized Myasthenia Gravis
Transient Neonatal Myasthenia Gravis
Ocular Myasthenia Gravis
Chapter 7 Market Breakdown by Treatment Modality
Introduction
Medications
Surgery
Intravenous Therapy
Chapter 8 Market Breakdown by Type of Product
Monoclonal Antibodies
Brands
Cholinesterase Inhibitors
Brand
Intravenous Immunoglobulins
Brands
Immunosuppressants
Brand
Corticosteroids
Brand
Chapter 9 ESG Development
Introduction
Environment
Social
Governance
Case Study
AstraZeneca
Concluding Remarks from BCC Research
Chapter 10 Emerging Technologies and Developments
Introduction
Chapter 11 Competitive Intelligence
Overview
Industry Scenario
Company Shares
Chapter 12 Patent Analysis
Patent Analysis by Manufacturer
Chapter 13 Pipeline Analysis
Clinical Trials
Chapter 14 M&A and Venture Funding Outlook
Introduction
Chapter 15 Company Profiles
ABBVIE
AMYASTHENIA GRAVISEN INC.
ASTELLAS PHARMA INC.
ASTRAZENECA
BAUSCH HEALTH COMPANIES INC.
BAYER AG
BIOGEN
BRISTOL-MYERS SQUIBB
CSL
DAIICHI SANKYO CO. LTD.
F. HOFFMANN-LA ROCHE AG
GILEAD SCIENCES INC.
GLAXOSMITHKLINE PLC.
MERCK & CO. INC.
NOVARTIS
PFIZER INC.
SANOFI
SERVIER LABORATORIES
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Chapter 16 Appendix: Acronyms